Acute and chronic kidney disease after pediatric liver transplantation: An underestimated problem.
calcineurin inhibitors
chronic kidney disease
nephrotoxicity
pediatric liver transplantation
renal biomarkers
renal function estimation
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
01
03
2020
revised:
02
08
2020
accepted:
15
08
2020
pubmed:
20
9
2020
medline:
24
6
2021
entrez:
19
9
2020
Statut:
ppublish
Résumé
Acute and chronic kidney injuries represent critical issues after liver transplantation (LTx), but whereas renal dysfunction in adult transplant patients is well documented, little is known about its prevalence in childhood. It is a challenge to accurately evaluate renal function in patients with liver disease, due to several confounding factors. Creatinine-based equations estimating glomerular filtration rate, validated in nephropathic patients without hepatic issues, are frequently inaccurate in end-stage liver disease, underestimating the real impact of renal disease. Moreover, whereas renal issues observed within 1 year from LTx were often related to acute injuries, kidney damage observed after 5-7 years from LTx, is due to chronic, irreversible mechanisms. Most immunosuppression protocols are based on calcineurin inhibitors (CNIs) and corticosteroids, but mycophenolate mofetil or sirolimus could play significant roles, also in children. Early diagnosis and personalized treatment represent the bases of kidney disease management, in order to minimize its close relation with increased mortality. This review analyzed acute and chronic kidney damage after pediatric LTx, also discussing the impact of pre-existent renal disease. The main immunosuppressant strategies have been reviewed, highlighting their impact on kidney function. Different methods assessing renal function were reported, with the potential application of new renal biomarkers.
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Mycophenolic Acid
HU9DX48N0T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14082Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Getsuwan S, Tanpowpong P, Lertudomphonwanit C, et al. Health-related quality of life in pediatric liver transplant recipients. Transplant Proc. 2020;13:30112-30113.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med. 2003;349:931-940.
Herzog D, Martin S, Turpin S, et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation. 2006;81:672-677.
de Souza V, Cochat P, Rabilloud M, et al. Accuracy of different equations in estimating GFR in pediatric kidney transplant recipients. Clin J Am Soc Nephrol. 2015;10:463-470.
Tøndel C, Bolann B, Salvador CL, et al. Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatr Nephrol. 2017;32(2):311-320.
Filler G, Bendrick-peart J, Strom T, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant. 2009;13:44-53.
Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant. 2011;30:1352-1359.
Grenda R, Prokurat S, Ciechanowicz A, Piatosa B, Kalicinski P. Evaluation of the genetic background of standard-immunosuppressant- related toxicity in a cohort of 200 paediatric renal allograft recipients-a retrospective study. Ann Transplant. 2009;14:18-24.
Dell-Olio D, Kelly DA. Calcineurin inhibitor minimization in pediatric liver allograft recipients. Pediatr Transplant. 2009;13:670-681.
Turmelle YP, Nadler ML, Anderson CD, Doyle MB, Lowell JA, Shepherd RW. Towards minimizing immunosuppression in pediatric liver transplant recipients. Pediatr Transplant. 2009;13:553-559.
Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4(1):207-220.
Massonnet B, Delwail A, Ayrault J-M, et al. Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation. Clin Exp Immunol. 2009;158:115-124.
Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018;94:674-681.
Alghamdi SA, Saadah OI, Almatury N, Al-Maghrabi J. Hepatic-associated immunoglobulin-A nephropathy in a child with liver cirrhosis and portal hypertension. Saudi J Gastroenterol. 2012;18(3):214-216.
Harambat J, Ranchin B, Dubourg L, et al. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation. 2008;86:1028-1034.
Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-337.
Mekahli D, van Stralen KJ, Bonthuis M, et al. kidney versus combined kidney and liver transplantation in young people with autosomal recessive polycystic kidney disease: data from the European society for pediatric nephrology/european renal association-european dialysis and transplant (ESPN/ERA-EDTA) Registry. Am J Kidney Dis. 2016;68:782-788.
Burgmaier K, Kilian S, Bammens B, et al. Clinical courses and complications of young adults with autosomal recessive polycystic kidney disease (ARPKD). Sci Rep. 2019;9:7919.
Lacquaniti A, Caccamo C, Salis P, et al. Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. Biomarkers. 2016;21:371-378.
Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care. 2010;14:214.
Mattman A, Eintracht S, Mock T, et al. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J Am Soc Nephrol. 2006;17:487.
Davenport A. Difficulties in assessing renal function in patients with cirrhosis-potential impact on patient treatment. Intensive Care Med. 2011;37:930-932.
Kuster N, Bargnoux AS, Pageaux GP, Cristol JP. Limitations of compensated Jaffe creatinine assays in cirrhotic patients. Clin Biochem. 2012;45:320-325.
Bharat W, Manlhiot C, McCrindle BW, et al. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr Transplant. 2009;13:111-118.
Groesbeck D, Köttgen A, Parekh R, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol. 2008;3:1777-1785.
Cimerman N, Mesko Brguljan P, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta. 2000;300:83-95.
Bokenkamp A, van Wijk J, Lentze M, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta 2-microglobulin concentrations. Clin Chem. 2002;48:1123-1126.
Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl. 2005;11:344-349.
Brinkert F, Kemper MJ, Briem-Richter A, van Husen M, Treszl A, Ganschow R. High prevalence of renal dysfunction in children after liver transplantation: non-invasive diagnosis using a cystatin C-based equation. Nephrol Dial Transplant. 2011;26:1407-1412.
Gowrishankar M, VanderPluym C, Robert C, Bamforth F, Gilmour S, Senthilselvan A. Value of serum cystatin C in estimating renal function in children with non-renal solid organ transplantation. Pediatr Transplant. 2015;19:27-34.
Lacquaniti A, Donato V, Pintaudi B, et al. "Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50:935-942.
Lacquaniti A, Buemi F, Lupica R, et al. Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy? Radiology. 2013;267:86-93.
Tsuchimoto A, Shinke H, Uesugi M, et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One. 2014;9:e110527.
Sirota JC, Walcher A, Faubel S, et al. Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol. 2013;14:17.
Abraham BP, Frazier EA, Morrow WR, et al. Cystatin C and neutrophil gelatinase associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplantation. 2011;15:564-569.
Thomas ME, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):pp. 62-73. 14.
Sutherland SM, Byrnes JJ, Kothari M, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. Clin J Am Soc Nephrol. 2015;10(4):554-561.
Schumacher KR, Gajarski RJ. Postoperative care of the transplanted patient. Curr Cardiol Rev. 2011;7(2):110-122. 29.
Tannuri U, Tannuri AC. Postoperative care in pediatric liver transplantation. Clinics (Sao Paulo). 2014;69(Suppl 1):42-46.
Ferah O, Akbulut A, Açik ME, et al. Acute kidney injury after pediatric liver transplantation. Transplant Proc. 2019;51:2486-2491.
Hamada M, Matsukawa S, Shimizu S, Kai S, Mizota T. Acute kidney injury after pediatric liver transplantation: incidence, risk factors, and association with outcome. J Anesth. 2017;31:758-763.
Bartosh SM, Alonso EM, Whitington PF. Renal outcomes in pediatric liver transplantation. Clin Transplant. 1997;11:354-360.
Nahum E, Kadmon G, Kaplan E, et al. Prevalence of acute kidney injury after liver transplantation in children: comparison of the pRIFLE, AKIN, and KDIGO criteria using corrected serum creatinine. J Crit Care. 2019;50:275-279.
Chae MS, Lee N, Park DH, et al. “Influence of oxygen content immediately after graft reperfusion on occurrence of postoperative acute kidney injury in living donor liver transplantation. Medicine. 2017;96:e7626.
Atalan HK, Gucyetmez B, Aslan S, Yazar S, Polat KY. “Postoperative acute kidney injury in living donor liver transplantation recipients. Int J Artificial Organs. 2018;41:37-42.
Zhang Y, Xiang B, Wu Y, Xie X, Wang J, Jjin S. Risk factors and associated outcomes of early acute kidney injury in pediatric liver transplant recipients: a retrospective study". J Pediatr Surg. 2020;55:781.
Longenecker JC, Estrella MM, Segev DL, Atta MG. Patterns of kid-ney function before and after orthotopic liver transplant: associations with length of hospital stay, progression to end- stage renal disease, and mortality. Transplantation. 2015;99:2556-2564.
Williams C, Borges K, Banh T, et al. Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients. Am J Transplant. 2018;18:1481-1488.
Abdel Jalil MH, Hawwa AF, McKiernan PJ, Shields MD, McElnay JC. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol. 2014;77:130-140.
Shellmer DA, Dabbs AD, Dew MA. Medical adherence in pediatric organ transplantation: what are the next steps? Curr Opin Organ Transplant. 2011;16:509-514.
Kaliciński P, Szymczak M, Smirska E, et al. Longitudinal study of renal function in pediatric liver transplant recipients. Ann Transplant. 2005;10:53-58.
Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am SocNephrol. 2009;4:481-508.
McDiarmid SV. Renal function in pediatric liver transplant patients. Kidney Int Suppl. 1996;53:S77-S84.
Arora-Gupta N, Davies P, McKiernan P, Kelly DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant. 2004;8(2):145-150.
Redondo-Horcajo M, Lamas S. Oxidative and nitrosative stress in kidney disease: a case for cyclosporine A. J. Nephrol. 2005;18:453-457.
Chang CT, Hung CC, Tian YC, Yang CW, Wu MS. Ciclosporin reduces paracellin-1 expression and magnesium transport in thick ascending limb cells. Nephrol Dial Transplant. 2007;22:1033-1040.
Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc. 2004;36:S234-S239.
Mengel M, Mihatsch M, Halloran PF. Histological characteristics of calcineurin inhibitor toxicity-there is no such thing as specificity. Am J Transplant. 2011;11:2549-2550.
Kim J-Y, Akalin E, Dikman S, et al. The variable pathology of kidney disease after liver transplantation. Transplantation. 2010;89(2):215-221.
Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant. 2010;10(9):2017-2025.
Mourer JS, Hartigh J, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation. 2012;93:887-894.
Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14:69-96.
Kwong A, Kim WR, Lake JR, et al. OPTN/SRTR 2018 annual data report: liver. Am J Transplant. 2020;20(s1):193-299.
Aw MM, Samaroo B, Baker AJ, et al. Calcineurin-related nephrotoxicity: reversibility in pediatric liver transplant recipients. Transplantation. 2001;72:746-749.
Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: changes in the immune response. Pediatr Transplant. 2004;8:454-459.
Tannuri U, Gibelli NEM, Maksoud-Filho JG, et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transplant. 2007;11:82-86.
Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation. 2005;79:1575-1580.
Cransberg K, Cornelissen M, Lilien M, et al. Maintenance immunosuppression with mycophenolate mofetil and cortico steroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation. 2007;83:1041-1047.
Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Liver Transpl. 2007;13:1570-1575.
Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M. Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet. 2017;60:16-22.
Vondrak K, Parisi F, Dhawan A, et al. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. Clin Transplant. 2019;33:e13698.
Stifft F, Stolk L, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2014;97:775-780.
Kuypers DRJ, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a random- ized controlled trial using electronic monitoring. Transplantation. 2013;95:333-340.
Adam R, Karam V, Delvart V, et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant. 2015;15:1267-1282.
Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year postconversion in stable pediatric liver transplant recipients. Am J Transplant. 2007;7:1609.
Quintero J, Juampérez J, Ortega J, et al. Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients a long-term prospective study. Transpl Int. 2018;31:38.
Carcas-Sansuán AJ, Hierro L, Almeida-Paulo GN, et al. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up. Liver Transplant. 2013;19:1151.
FDA. 2009; http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015.htm.
Wiesner R, Kintmalm HG, McDiamid S, et al. Sirolimus Immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am J Transplant. 2002;2:464.
Wiesner R, for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus vs. tacrolimus in de novo orthotopic liver transplant recipients: results from a pilot study. Hepatology. 2002;36:208.
Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transplant Int. 2010;23:155-168.
Everson G. Everolimus and mTOR inhibitors in liver transplantation: opening the ‘‘Box’’. Liver Transpl. 2006;12:1571-1573.
Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. Am J Transplant. 2012;12:1855-1865.
Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640-1648.
Saliba F, De Simone P, Nevens F, et al. H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734-1745.
Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B, Ganschow R. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr Transplant. 2011;15:510-514.
Weymann A, Ganschow R, Ericzon B, et al. Efficacy and safety of everolimus with reduced tacrolimus or cyclosporine in pediatric liver transplant recipients: 12-month results from H2305 study. Am J Transplant. 2017;17:1435-1446.
Ganschow R, Ericzon BG, Dhawan A, et al. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: results from a multicenter, prospective study. Pediatr Transplant. 2017;21:e13024.
Dumortier J, Couchonnal E, Lacaille F, et al. mTOR inhibitors in pediatric liver transplant recipients. Clin Res Hepatol Gastroenterol. 2019;43:403-409.
Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535-546.
Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001;72:449-454.
Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012;307:283-293.
Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol. 2007;17(94-97):97.
Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007;7:309-319.
Bourdeaux C, Darwish A, Jamart J, et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant. 2007;7:440.
Matloff RG, Arnon R, Saland JM. The kidney in pediatric liver transplantation: an updated perspective. Pediatr Transplant. 2012;16:818-828.
Bishop JR, Burniston MT, Barnfield MC, et al. Renal function evaluated by measured GFR during follow-up in pediatric liver transplant recipients. Pediatr Transplant. 2009;13:96-103.
Menon S, Pollack AH, Sullivan E, Murphy T, Smith J. Acute kidney injury and chronic kidney disease after non-kidney solid organ transplantation. Pediatr Transplant. 2020;24(6):e13753.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
O’Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant. 2007;7:168-176.
Mention K, Lahoche-Manucci A, Bonnevalle M, et al. Renal function outcome in pediatric liver transplant recipients. Pediatr Transplantation. 2005;9:201-207.
Kivelä JM, Räisänen-Sokolowski A, Pakarinen MP, et al. Long-term renal function in children after liver transplantation. Transplantation. 2011;91:115-120.
Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr. 2006;148:475-480.
Filler G, Sharma AP. How to monitor renal function in pediatric solid transplant recipients. Peditr Transplantation. 2008;12:393-401.
Prytula A, Vandekerckhove K, Raes A, et al. tacrolimus predose concentration is associated with hypertension in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr. 2016;63:616-623.
Bayrakci US, Baskin E, Ozcay F, et al. Abnormal circadian blood pressure regulation in liver transplanted children. Pediatr Transplant. 2012;16:160-164.
Anastaze Stelle K, Belli DC, Parvex P, et al. Glumerular and tubular function following orthotopic liver transplantation in children treated with tacrolimus. Pediatr transplant. 2012;16:250-256.
Li L-C, Hsu C-N, Lin C-C, et al. Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients. BMC Gastroenterol. 2017;17:58.
Ruebner RL, Reese PP, Denburg MR, et al. Risk factors for end-stage kidney disease after pediatric liver transplantation. Am J Transplant. 2012;12:3398-3405.
Midtvedt K. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:S430-S433.
Kavukçu S, Soylu A, Türkmen M, Kasap B, Gümüştekin M, Gülay H. Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late posttransplant period. Pediatr Nephrol. 2004;19:667-671.
Schnitzbauer AA, Sothmann J, Baier L, et al. Calcineurin inhibitor free de novoimmunosuppression in liver transplant recipients with pretrans-plant renal impairment: results of a Pilot Study (PATRON07). Transplantation. 2015;99:2565-2575.